Business
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high response rates with multiple complete responsesPatients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapyMeeting with FDA has now been requested to discuss next steps including potential paths to approval SYDNEY, AUSTRALIA, May 05,
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":246,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIIfOSI4irhaeByOTtn6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578","width":246,"height":103}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Mature overall survival data builds on encouraging high response rates with multiple complete responses","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapy","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Meeting with FDA has now been requested to discuss next steps including potential paths to approval","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":479,"olType":false},{"type":"text","content":"SYDNEY, AUSTRALIA, May 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This part of the Phase II study evaluates eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line therapy in recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with PD-L1 expression below 1 (Combined Positive Score [CPS] <1).","length":706,"tagName":"p"},{"type":"text","content":"The mature 17.6-months median OS in evaluable patients (N=31) with a data cut-off of 31 March 2025 compares favourably to historical results from the two current standard-of-care approaches for 1L HNSCC patients with CPS <1 including 10.7-months from c...